Search

EHA Blood Cancer Awareness Month Wrap-up

The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

IVDR resources

IVD Taskforce Videos:Konstanze Döhner

\
 

Monika Brüggemann

IVDR Sessions:

HemaSphere articles:
Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
EU-Wide Access to…

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Meet our Volunteers of the Month: Elizabeth, Francesca and Verena

Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.

Read more

Meet our Volunteers of the Month: Elizabeth, Francesca and Verena

Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.

Read more

EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023

On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.

Read more